Phase I Study of Ipilimumab (Anti-CTLA-4) in Children and Adolescents With Treatment-Resistant Cancer

Clinical Trial ID NCT01445379

Rank	Title	Journal	Year	PubWeight™‹?›
1	Immunosuppressive networks in the tumour environment and their therapeutic relevance.	Nat Rev Cancer	2005	10.06
2	The three Es of cancer immunoediting.	Annu Rev Immunol	2004	8.20
3	Cancer surveillance series: recent trends in childhood cancer incidence and mortality in the United States.	J Natl Cancer Inst	1999	2.38
4	Combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma.	J Immunother Cancer	2015	1.02
5	Cancer immunotherapy in clinical practice -- the past, present, and future.	Chin J Cancer	2014	0.98
6	Immunotherapy for solid tumors--a review for surgeons.	J Surg Res	2013	0.83
7	Recent new drug approvals, part 2: drugs undergoing active clinical studies in children.	J Pediatr Pharmacol Ther	2013	0.82
8	Immunotherapy of Childhood Sarcomas.	Front Oncol	2015	0.81
9	Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors.	Clin Cancer Res	2015	0.80
10	Immunotherapy in pediatric malignancies: current status and future perspectives.	Future Oncol	2014	0.78
11	Adoptive cell therapy for sarcoma.	Immunotherapy	2015	0.78
12	Antibody therapy of pediatric B-cell lymphoma.	Front Oncol	2013	0.75